Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a strong-buy rating to a buy rating in a ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

According to 26 different analyst ratings, Novo (NYSE:NVO) has the highest target price of $168.39 which means it could more than double from the current levels if the optimistic scenario unfolds. A ...